AIM ImmunoTech Announces Print Publication Of Data Analysis From Early Access Program Studying Ampligen
Portfolio Pulse from Benzinga Newsdesk
AIM ImmunoTech Inc. announced the print publication of data from an Early Access Program studying Ampligen for advanced pancreatic cancer, published in Clinical Cancer Research.
August 20, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AIM ImmunoTech's data on Ampligen for advanced pancreatic cancer has been published in a prestigious journal, potentially boosting investor confidence and interest in the company's research capabilities.
The publication in a prestigious journal highlights the potential of Ampligen in treating advanced pancreatic cancer, which could lead to increased investor interest and a positive impact on AIM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100